Skip to main content
EU joint undertaking

IMI 2 Joint Undertaking (IMI 2 JU)

Logo of IMI 2 Joint Undertaking

Overview

  • Role: To advance the development of medicines by facilitating open collaboration on research
  • Director: Pierre Meulien
  • Partners: European Union (represented by the European Commission) and the European Federation of Pharmaceutical Industries and Associations (EFPIA)
  • Established in: 2008
  • Number of staff: 37
  • Location: Brussels (Belgium)
  • WebsiteIMI 2 Joint Undertaking (IMI 2 JU)

Developing new medicines is difficult, costly, inefficient and time-consuming. The Innovative Medicines Initiative Joint Undertaking (IMI 2 Joint Undertaking) supports collaborative research to improve the entire development process and make it more efficient, giving patients faster access to better and safer medicines.

What it does

It improves and speeds up the development of medicines by supporting open collaboration on research to address shared challenges.

It funds collaborative research projects that bring together all the parties involved in health research, including:

  • universities
  • the pharmaceutical and other industries
  • small and medium-sized businesses
  • patient organisations
  • medicine regulators.

This approach brings results in areas of disease where safe, effective treatments are lacking (e.g. dementia) and/or where the impact on public health is greatest (e.g. diabetes, antimicrobial resistance). The Innovative Medicines Initiative Joint Undertaking also runs projects on cross-cutting issues such as medicine safety and big data.

Who benefits

  • Patients can influence research into their conditions; in the longer term, they and society in general will benefit from faster access to better, safer medicines.
  • Academic researchers and small and medium-sized businesses gain access to research funding.
  • Pharmaceutical companies gain knowledge and tools to improve their research and development activities.
  • All project participants benefit from the expertise of other partners and the opportunity to translate scientific discoveries into useful tools, thereby advancing the development of medicines.

Further information

Calls for proposals

Project factsheets

Press releases

Monthly newsletter

Contact

IMI 2 Joint Undertaking

Website
Email
Phone number
+32 2 221 81 81
Postal address
IMI 2 Joint Undertaking, Avenue de la Toison d'Or 56-60/Gulden-Vlieslaan 56-60, 1060 Bruxelles / Brussel, Belgium
Social media